Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, u
Target Price
The average target price of SANION.ST is 19 and suggests 23% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell